Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
R-Pharm clinical trials
The registry lists 78 studies whose lead sponsor is R-Pharm or one of 2 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the R-Pharm studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to R-Pharm.
- R-Pharm58 studiesSame company
Something wrong?
- R-Pharm International, LLC17 studies →Subsidiary
Something wrong?
- R-Pharm Overseas, Inc.3 studies →Regional office
Something wrong?
Focus areas
Conditions R-Pharm leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 78. Browse all 78 →
- Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverNot yet recruitingNCT07880886Phase 3
- Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseNot yet recruitingNCT07625384Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIRecruitingNCT07543744Phase 1
- Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisRecruitingNCT07517575Phase 2
Sponsor listed in the registry: R-Pharm International, LLC
- Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverRecruitingNCT05190991Phase 2
Sponsor listed in the registry: R-Pharm International, LLC
- Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesRecruitingNCT06440746Phase 2/3
Sponsor listed in the registry: R-Pharm International, LLC
- Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1
- Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3
- A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingNCT07597668Phase 1
- A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435324Phase 3
- A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435311Phase 1
- A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3
- Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)Active, not recruitingNCT07670546Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT07553988Phase 2
Sponsor listed in the registry: R-Pharm International, LLC
- Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersCompletedNCT07206043Phase 1
Sponsor listed in the registry: R-Pharm International, LLC
- Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineActive, not recruitingNCT05092776Phase 2
Sponsor listed in the registry: R-Pharm International, LLC
- Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler SyndromeWithdrawnNCT04213274Phase 2
Sponsor listed in the registry: R-Pharm Overseas, Inc.
- Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)WithdrawnNCT05432960Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent PericarditisSuspendedNCT05107934Phase 2/3
Sponsor listed in the registry: R-Pharm Overseas, Inc.
- Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisActive, not recruitingNCT05673902Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4CompletedNCT04246762Phase 1
Sponsor listed in the registry: R-Pharm International, LLC
- Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial InfarctionCompletedNCT04463251Phase 2
Sponsor listed in the registry: R-Pharm Overseas, Inc.
- Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and FlutterCompletedNCT05773170
- Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisCompletedNCT03120949Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760368Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760407Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active DiseaseCompletedNCT02760433Phase 3
Sponsor listed in the registry: R-Pharm International, LLC
- Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired PneumoniaCompletedNCT03551210Phase 3
- Study of Efficacy of Different Treatment Regimens of OlokizumabStatus unknownNCT05187793Phase 3
- Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19CompletedNCT04501783Phase 3
- Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) InfectionCompletedNCT05196477
- Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent PericarditisCompletedNCT04692766Phase 2/3
Sponsor listed in the registry: R-Pharm International, LLC
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT04246723Phase 2
- Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedNCT04760730Phase 1/2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackTerminatedNCT04067492Phase 2
- Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedNCT04686773Phase 2
- Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19CompletedNCT04684446Phase 1/2
- Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)CompletedNCT04380519Phase 2/3
Sponsor listed in the registry: R-Pharm International, LLC
- Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy SubjectsCompletedNCT02667639Phase 1
- Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).WithdrawnNCT04452474Phase 2/3
- Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00080301Phase 3
- Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.CompletedNCT00162136Phase 1
- Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced CancerCompletedNCT00207090Phase 1
- Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00082433Phase 3
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerCompletedNCT00723957Phase 2
- Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric CancerCompletedNCT00983801Phase 2
- Phase I Combination Ixabepilone + CisplatinCompletedNCT00832117Phase 1
- Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol DependenceCompletedNCT03663374Phase 3
- A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched VolunteersCompletedNCT03832426Phase 1
- Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.CompletedNCT03575702Phase 3